Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ascoli Piceno – page 2

21 clinical trials in Ascoli Piceno, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ascoli Piceno at a glance
21
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

21 trials in Ascoli Piceno

Open in trial search

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Study on Prednisone and Vitamin D for Elderly Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Colecalciferol
  • Sponsor:Fondazione Italiana Linfomi Ets

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Ascoli Piceno

What the registry says about research in the country

01 Hematologic Malignancies

Groundbreaking research focusing on acute myeloid leukemia and multiple myeloma treatments, evaluating novel therapeutic combinations and stem cell transplantation approaches.

  • Leukemia Treatment Protocols
  • Stem Cell Transplantation
  • Novel Drug Combinations

Studies examining innovative conditioning regimens and targeted therapies for improved patient outcomes.

02 Lymphoma Research

Clinical investigations centered on follicular lymphoma and diffuse large B-cell lymphoma, exploring immunotherapy and chemotherapy combinations.

  • Immunochemotherapy Protocols
  • Maintenance Strategies
  • Treatment Optimization

Evaluating shortened versus standard chemotherapy regimens combined with innovative immunotherapy approaches.

03 Blood Disorders

Research focusing on conditions like paroxysmal nocturnal hemoglobinuria and autoimmune hemolytic anemia, testing new therapeutic agents.

  • Novel Drug Safety
  • Long-term Efficacy
  • Treatment Tolerability

Investigating breakthrough treatments for rare blood disorders with emphasis on patient safety and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.